Dr. Gerald Dryden, MD

Gastroenterology Louisville, KY Male
NPI: 1619969011
Total Payments
$2.6M
2024 Payments
$535,577
Companies
29
Transactions
1,685
Medicare Patients
485
Medicare Billing
$48,401

Payment Breakdown by Category

Other$2.1M (81.5%)
Travel$285,597 (11.1%)
Consulting$126,485 (4.9%)
Food & Beverage$38,324 (1.5%)
Research$23,698 (0.9%)
Education$195.70 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2.1M 558 80.3%
Travel and Lodging $285,597 497 11.1%
Consulting Fee $126,485 50 4.9%
Food and Beverage $38,324 547 1.5%
Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $25,200 8 1.0%
Unspecified $23,698 13 0.9%
Honoraria $6,329 7 0.2%
Education $195.70 5 0.0%

Payments by Type

General
$2.5M
1,672 transactions
Research
$23,698
13 transactions

Top Paying Companies

Company Total Records Latest Year
Takeda Pharmaceuticals U.S.A., Inc. $601,760 284 $0 (2024)
ABBVIE INC. $589,994 464 $0 (2024)
Janssen Scientific Affairs, LLC $553,357 343 $0 (2024)
Janssen Biotech, Inc. $221,153 143 $0 (2024)
Takeda Pharmaceuticals America, Inc. $168,407 91 $0 (2017)
Phathom Pharmaceuticals, Inc. $108,220 77 $0 (2024)
Lilly USA, LLC $97,134 51 $0 (2024)
Synergy Pharmaceuticals Inc $69,139 58 $0 (2018)
PFIZER INC. $43,495 28 $0 (2024)
Salix Pharmaceuticals, a division of Bausch Health US, LLC $21,932 28 $0 (2020)

Payment History by Year

Year Amount Transactions Top Company
2024 $535,577 324 ABBVIE INC. ($140,514)
2023 $269,257 158 AbbVie Inc. ($136,669)
2022 $357,569 225 Takeda Pharmaceuticals U.S.A., Inc. ($146,826)
2021 $169,424 107 Janssen Scientific Affairs, LLC ($78,841)
2020 $156,492 98 Janssen Scientific Affairs, LLC ($65,130)
2019 $245,179 197 Janssen Scientific Affairs, LLC ($112,922)
2018 $376,430 258 Takeda Pharmaceuticals U.S.A., Inc. ($183,619)
2017 $454,262 318 Takeda Pharmaceuticals America, Inc. ($168,407)

All Payment Transactions

1,685 individual payment records from CMS Open Payments — Page 1 of 68

Date Company Product Nature Form Amount Type
12/17/2024 ABBVIE INC. RINVOQ (Biological), SKYRIZI Food and Beverage In-kind items and services $28.36 General
Category: IMMUNOLOGY
12/13/2024 Lilly USA, LLC OMVOH (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,600.00 General
Category: Immunology
12/10/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,050.00 General
Category: Immunology
12/10/2024 Lilly USA, LLC OMVOH (Drug) Food and Beverage In-kind items and services $17.96 General
Category: Immunology
12/07/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $6,300.00 General
Category: Immunology
12/05/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Food and Beverage In-kind items and services $128.00 General
Category: Immunology
12/03/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Travel and Lodging In-kind items and services $800.39 General
Category: Immunology
12/03/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Travel and Lodging In-kind items and services $652.88 General
Category: Immunology
12/03/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Food and Beverage In-kind items and services $100.80 General
Category: Immunology
11/20/2024 ABBVIE INC. RINVOQ (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,900.00 General
Category: IMMUNOLOGY
11/19/2024 Celltrion USA Inc. ZYMFENTRA (Biological) Food and Beverage In-kind items and services $16.86 General
Category: GASTROENTEROLOGY
11/16/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,050.00 General
Category: Immunology
11/16/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,800.00 General
Category: Immunology
11/09/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $6,300.00 General
Category: Immunology
11/09/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,800.00 General
Category: Immunology
11/08/2024 ABBVIE INC. RINVOQ (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,900.00 General
Category: IMMUNOLOGY
11/08/2024 ABBVIE INC. RINVOQ (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,900.00 General
Category: IMMUNOLOGY
11/07/2024 ABBVIE INC. RINVOQ (Biological) Food and Beverage In-kind items and services $116.64 General
Category: IMMUNOLOGY
11/05/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Food and Beverage In-kind items and services $120.35 General
Category: Immunology
11/05/2024 ABBVIE INC. RINVOQ (Biological), SKYRIZI Food and Beverage In-kind items and services $21.93 General
Category: IMMUNOLOGY
11/05/2024 ABBVIE INC. RINVOQ (Biological), SKYRIZI Food and Beverage In-kind items and services $7.75 General
Category: IMMUNOLOGY
10/29/2024 ABBVIE INC. SKYRIZI (Biological), RINVOQ Food and Beverage In-kind items and services $27.08 General
Category: IMMUNOLOGY
10/28/2024 Janssen Biotech, Inc. STELARA (Biological), TREMFYA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $6,300.00 General
Category: Immunology
10/25/2024 PFIZER INC. VELSIPITY (Drug) Travel and Lodging In-kind items and services $532.00 General
Category: INFLAMMATION;PAIN
10/19/2024 Janssen Biotech, Inc. TREMFYA (Drug), STELARA Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,050.00 General
Category: Immunology
123…68»

Research Studies & Clinical Trials

Study Name Company Amount Records
A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) Eli Lilly and Company $8,901 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis E.R. Squibb & Sons, L.L.C. $5,775 2
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohn's Disease E.R. Squibb & Sons, L.L.C. $4,025 2
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE Eli Lilly and Company $2,466 4
A Randomized Double Blind Placebo Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate to Severe Crohn s Disease E.R. Squibb & Sons, L.L.C. $2,450 1
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE Eli Lilly and Company $80.86 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 3 68 80 $32,193 $6,273
2022 6 117 136 $55,471 $11,694
2021 5 98 123 $40,284 $10,086
2020 8 202 252 $91,813 $20,349
Total Patients
485
Total Services
591
Medicare Billing
$48,401
Procedure Codes
22

All Medicare Procedures & Services

22 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 30 38 $9,652 $3,149 32.6%
45380 Biopsy of large bowel using a flexible endoscope Facility 2023 17 17 $18,241 $1,636 9.0%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 21 25 $4,300 $1,487 34.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 28 37 $9,398 $3,007 32.0%
99222 Initial hospital inpatient care per day, typically 50 minutes Facility 2022 25 25 $8,300 $2,427 29.2%
45385 Removal of polyps or growths of large bowel using an endoscope with mechanical snare Facility 2022 11 11 $13,365 $1,957 14.6%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 25 29 $4,988 $1,700 34.1%
45380 Biopsy of large bowel using a flexible endoscope Facility 2022 15 15 $16,095 $1,578 9.8%
99232 Follow-up hospital inpatient care per day, typically 25 minutes Facility 2022 13 19 $3,325 $1,024 30.8%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 27 34 $8,636 $3,160 36.6%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 19 35 $6,125 $1,936 31.6%
45380 Biopsy of the large bowel using an endoscope (colonoscopy) Facility 2021 14 15 $16,095 $1,867 11.6%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 17 17 $5,644 $1,779 31.5%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 21 22 $3,784 $1,345 35.5%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2020 51 55 $18,260 $5,944 32.6%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 43 71 $12,425 $4,041 32.5%
45385 Removal of polyps or growths of large bowel using an endoscope Facility 2020 13 13 $15,795 $2,511 15.9%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 26 36 $9,144 $2,501 27.3%
43235 Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope Facility 2020 17 18 $13,032 $1,520 11.7%
99213 Established patient office or other outpatient visit, typically 15 minutes Office 2020 26 30 $5,160 $1,387 26.9%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 13 16 $4,048 $1,251 30.9%
45380 Biopsy of large bowel using an endoscope Facility 2020 13 13 $13,949 $1,194 8.6%

About Dr. Gerald Dryden, MD

Dr. Gerald Dryden, MD is a Gastroenterology healthcare provider based in Louisville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619969011.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerald Dryden, MD has received a total of $2.6M in payments from pharmaceutical and medical device companies, with $535,577 received in 2024. These payments were reported across 1,685 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.1M).

As a Medicare-enrolled provider, Dryden has provided services to 485 Medicare beneficiaries, totaling 591 services with total Medicare billing of $48,401. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.

Practice Information

  • Specialty Gastroenterology
  • Other Specialties Internal Medicine
  • Location Louisville, KY
  • Active Since 08/22/2005
  • Last Updated 02/14/2017
  • Taxonomy Code 207RG0100X
  • Entity Type Individual
  • NPI Number 1619969011

Products in Payments

  • STELARA (Biological) $704,201
  • Entyvio (Biological) $396,724
  • ENTYVIO (Biological) $352,419
  • RINVOQ (Biological) $285,645
  • Humira (Biological) $115,348
  • SKYRIZI (Biological) $111,883
  • VOQUEZNA (Drug) $108,220
  • TREMFYA (Drug) $74,588
  • OMVOH (Drug) $74,382
  • Trulance (Drug) $69,139
  • HUMIRA (Biological) $39,352
  • VELSIPITY (Drug) $26,025
  • LINZESS (Drug) $17,486
  • XELJANZ (Drug) $17,469
  • TRULANCE (Drug) $12,083
  • XIFAXAN (Drug) $9,871
  • RELISTOR (Drug) $8,155
  • SOTYKTU (Drug) $8,050
  • ELEVIEW (Device) $7,122
  • MB MMX (Drug) $3,938

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Gastroenterology Doctors in Louisville

Jeffrey Tuvlin, Md, MD

Gastroenterology — Payments: $262,541

Gastroenterology $262,541

Dr. Sunana Sohi, M.d, M.D

Gastroenterology — Payments: $190,137

Gastroenterology $190,137

Dr. Michael Krease, D.o, D.O

Gastroenterology — Payments: $161,937

Gastroenterology $161,937

Stephen Mcclave, Md, MD

Gastroenterology — Payments: $147,518

Gastroenterology $147,518

Ashwani Singal, M.d.; M.sc, M.D.; M.SC

Gastroenterology — Payments: $42,847

Gastroenterology $42,847

Dr. Thomas Abell, Md, MD

Gastroenterology — Payments: $38,709

Gastroenterology $38,709